Navigation Links
Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

HAYWARD, Calif., April 10, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated announced data will be presented on the Company's clinical and preclinical pipeline, including its Hsp90 inhibitor, epothilone and nuclear export inhibitor programs, at the 2007 Annual Meeting of the American Association for Cancer Research (AACR), being held in Los Angeles, April 14-18, 2007.

Poster presentations on Kosan's programs are as follows. The location for all poster presentations is the Los Angeles Convention Center Exhibit Hall.


    Date   Abstract #   Title             Session          Poster  Poster #

                                                           Section

    4/15

    1:00-  1544         Tanespimycin:     Experimental     32      4

    5:00                 No effects on     and Molecular

                         QTC interval      Therapeutics 13

                         using two

                         formulations


    4/15

    1:00-  1568         Preclinical       Experimental     32      28

    5:00                 safety profile    and Molecular

                         of tanespimycin   Therapeutics 13

                         (KOS-5: 953) --

                         a heat shock

                         protein 90

                         (Hsp90)

                         inhibitor


    4/15

    1:00-  1438         KOS-1803: A new,  Experimental     27      19

    5:00                 rationally        and Molecular

                         designed          Therapeutics 8

                         epothilone

                         analog with an

                         improved

                         pharmacological

                         profile and

                         efficacy in

                         xenograft mouse

                         models


    4/18

    8:00-  5597         Anti-tumor        Experimental     29      2

    12:00                activity of       and Molecu
lar

                         novel nuclear     Therapeutics 47

                         export

                         inhibitors

                         (NEIs) in

                         multiple

                         xenograft

                         models


    4/18

    8:00-  5609         Nuclear Export    Experimental     29      14

    12:00                Inhibitors        and Molecular

                         (NEIs) as novel   Therapeutics 47

                         cancer

                         therapeutics


Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.

For additional information on Kosan Biosciences, please visit the company's website at www.kosan .com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements regarding anticipated presentations of data relating to Kosan's product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward- looking statements, including, among others, the risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2006 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward-looking statements.

NOTE: Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

CONTACT: Jane Green, VP, Corporate Communications of Kosan BiosciencesIncorporated, +1-510-731-5335, or mobile, +1-415-652-4819, or green@kosan.com

Web site: http://www.kosan.com/

Ticker Symbol: (NASDAQ-NMS:KOSN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
9. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... -- Research and Markets has announced the addition ... report to their offering. ... The global orthopedic navigation system ... Increasing geriatric population prone to orthopedic diseases is a key ... the forecast period. Osteoarthritis and osteoporosis are most common disorders ...
(Date:3/29/2017)... Mar 29, 2017  Providence Medical Technology, Inc., ... addition of two industry veterans to the commercial ... the company to lead Global Marketing, and ... Mr. Lynch and Mr. Scott have over 40 ... Mr. Lynch joins the company with over 22 ...
(Date:3/29/2017)... 29, 2017  The leader in accelerated orthodontics, OrthoAccel ... Sam Daher , Manal Ibrahim , Kenji ... will be the featured microlecture presenters at the AcceleDent ... of Orthodontists (AAO) Annual Session, April 21-25, 2017. Orthodontists ... beginning daily at 11:20 a.m. On the opening morning ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a premium medical cannabis ... the company’s executive management team with prominent executives from both inside and outside the ... Operating Officer, Ted Dumbauld , who has more than twenty years of business ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of the ... is touted to be the next revolution in our fight against this complex disease. ... form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a ...
(Date:3/29/2017)... ... ... The Wharton School of the University of Pennsylvania is pleased to announce that ... gift to establish the Ken Moelis and Julie Taffet Moelis Advance Access Program ... for highly-qualified Penn undergraduates whose academic and career interests expand traditional notions of business ...
(Date:3/28/2017)... Angeles, CA (PRWEB) , ... March 28, 2017 , ... ... call” asking the American public to take the Diabetes Risk Test to find out ... event, the Los Angeles World Airports will light up the evening sky by programming ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... (MRE), is pleased to be invited to the Siemens Healthineers annual customer education ... The event will take place from March 27 - 31, 2017 at ...
Breaking Medicine News(10 mins):